• Users Online: 215
  • Print this page
  • Email this page
Year : 2020  |  Volume : 7  |  Issue : 7  |  Page : 42-48

Pharmacological management of COVID-19

Department of Pediatric Critical Care, Medanta - The Medicity, Gurgaon, Haryana, India

Correspondence Address:
Dr. Maninder Singh Dhaliwal
Medanta - The Medicity, Gurgaon - 122 001, Haryana
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/JPCC.JPCC_66_20

Rights and Permissions

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) pandemic has brought the world to a standstill and is the largest public health crisis in the world in the present generation. As the cases continue to increase globally, and more patients are developing severe disease, large volumes of clinical data collection and aggressive research is being carried out to find effective medical therapies for this disease. No definitive proven treatment option exists till date. Various immunomodulatory and anti-viral drugs have shown potential, and are being studied extensively through randomized trials. The most available literature is based on the adult study population, with few/no children being included. This review attempts to summarize the pharmacotherapeutic options presently in consideration in children in the treatment of SARS-CoV2.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded294    
    Comments [Add]    
    Cited by others 1    

Recommend this journal